Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

First Study to Demonstrate That Lowering LDL Cholesterol With a PCSK9 Inhibitor Impacts Underlying Atherosclerotic Disease on top of Optimized Statin Therapy Intravascular Ultrasound Study Meets Primary and Secondary Endpoints Detailed Results to be Presented at AHA Scientific Sessions 2016

Amgen - Investors - RSS Content